Table 1. Demographic and Baseline Characteristics of Patients.
Characteristic | Valuea (N = 125) |
---|---|
Age, median (range), y | 62.0 (27-84) |
<65 | 74 (59.2) |
≥65 | 51 (40.8) |
ECOG performance status | |
0 | 60 (48.0) |
1 | 65 (52.0) |
Time since first diagnosis, median (range), y | 4.0 (0.8-24.3) |
Time since diagnosis of metastatic disease, median (range), y | 2.4 (0.03-17.2) |
No. of prior anticancer therapy lines for metastatic or locally advanced disease | |
0 | 5 (4.0) |
1 | 14 (11.2) |
2 | 25 (20.0) |
3 | 28 (22.4) |
4 | 22 (17.6) |
≥5 | 31 (24.8) |
Median (range) | 3 (0-10) |
Histologic type | |
Serous | 93 (74.4) |
Mucinous | 4 (3.2) |
Endometrioid | 3 (2.4) |
Clear cell | 2 (1.6) |
Transitional cell | 1 (0.8) |
Other | 3 (2.4) |
Uncoded or missing | 19 (15.2) |
CA125 level, IU/mL | |
<35 | 8 (6.4) |
35-70 | 13 (10.4) |
>70 | 52 (41.6) |
Unavailable | 52 (41.6) |
BRCA mutation status | |
Negative | 38 (30.4) |
Positiveb | 8 (6.4) |
Unknown | 79 (63.2) |
Abbreviations: CA125, cancer antigen 125; ECOG, Eastern Cooperative Oncology Group.
SI conversion factor: To convert CA125 to kilounits per liter, multiply by 1.0.
Data are presented as number (percentage) of patients unless otherwise indicated.
Deleterious mutation or mutation of uncertain significance.